MIDDLE EAST AND AFRICA GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Middle East and African Glucagon-Like Peptide-1 (GLP-1) Agonists Market is Segmented Into Drugs (Dulaglutide (Trulicity), Exenatide (Byetta and Bydureon), Liraglutide (Victoza), Lixisenatide (Lyxumia), and Semaglutide (Ozempic)), and Geography (Saudi Arabia, Egypt, Iran, South Africa, Oman, and Rest of Middle East and Africa). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

MIDDLE EAST AND AFRICA GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Industry Overview

The Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, holding their presence in all regions.

Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Leaders

  1. AstraZeneca

  2. Sanofi

  3. Eli Lilly and Company

  4. Novo Nordisk A/S

  5. Pfizer Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Concentration

Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?